Weight Loss Pens: Anvisa Investigates Cases of Vision Loss
10 Articles
10 Articles
Anvisa investigates 13 reports of suspected non-arteritic anterior ischemic optic neuropathy (Noia), a rare lesion in the optic nerve that can cause permanent loss of vision, in patients who used GLP-1 agonists class drugs, indicated for diabetes and obesity. The disease functions as a nerve infarction that binds the eye to the brain. Small vessels that irrigate it clog, part of the nerve cells dies and the vision of one of the eyes suddenly wor…
Rare lesion clogs the vessels of the optic nerve and may leave permanent sequelae; study points association with semaglutide, but relationship has not yet been proven The National Agency of Health Surveillance (Anvisa) investigates 13 reports of suspected non-arteritic anterior ischemic optic neuropathy (Noia) in patients who used drugs of the class of agonists [...]
Thirteen reports of suspected non-arteritic anterior ischemic optic neuropathy (Noia) are being investigated by Anvisa in patients who used weight-loss pens of medications indicated for the treatment of diabetes and obesity.The condition is a rare lesion in the optic nerve that can cause permanent loss of vision.The disease can be compared to a nerve infarction that connects the eye to the brain.The blockage of small vessels reduces blood flow t…
Anvisa investigates 13 notifications of Noia in users of pens for diabetes and weight loss; relationship with medications has not been proven.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
